China's Tianyin Pharmaceutical Receives Approval For Ofloxacin And Fleroxacin To Expand Antibiotic Product Line
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Tianyin Pharmaceutical, a Traditional Chinese Medicine and Western drug maker in China, announced it received manufacturing licenses from China's State FDA for its antibiotic products fluoroquinolone-based ofloxacin and quinolone broad-spectrum fleroxacin
You may also be interested in...
Tianyin Completes Government Commission For Post-quake Medicines, Expects Expanded Revenue Despite Disruption In Operation
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).